06 September 17 The Straits Times by ANNABETH LEOW
Erectile dysfunction sufferers could soon get a lift with a medical device maker opening a new urology headquarters here yesterday.
The facility in Jurong East will be a hub for Dornier MedTech to carry out clinical research and formulate regulatory and commercialisation strategies as it looks to break into various markets in the Asia-Pacific region.
It is set to add at least 30 jobs over the next five years, as part of the Temasek unit's US$30 million (S$40.7 million) regional investment.
The centre will lead and coordinate clinical trials for erectile dysfunction treatment with the company's Dornier Aries device. The second-generation version is now seeking regulatory approval in the United States.
The device offers a shockwave therapy that is being billed as a non-surgical, drug-free potential cure for penile problems.
Growth plans also involve exploring other ailments Aries can fix. Besides erectile dysfunction, urinary incontinence and chronic pelvic pain may also be addressed by the technology.
Impotence affects about one in 20 men in their 40s here.
The launch of the centre comes as the Government woos partners to build up research, development and commercialisation in the medical technology, or medtech, sector.
Economic Development Board chairman Beh Swan Gin noted at the centre's opening that Singapore is well placed to help global medtech companies navigate the diversity and complexities of Asia's regulatory landscape and clinical needs, accelerating their ability to develop and bring new products to regional and global markets.
We see Singapore increasingly playing such a role for medtech companies, building on our capabilities to drive innovation and create value in the global biomedical sciences industry.
Dr Beh added that efforts to develop a medtech ecosystem here will translate into new job opportunities for Singaporeans that will include global roles as well as specialist roles such as clinical application and regulatory affairs.
Dornier MedTech chief executive Abel Ang, who is also group CEO of parent company Accuron MedTech, said that the company has made good progress in hiring experts such as molecular biologists and material scientists in its shift from pre-clinical research to device production.
The Singapore-based Accuron MedTech is a division of Temasek Holdings' wholly owned subsidiary Accuron Technologies.